Key Highlights
- Loss per share was USD 4.52 against an estimate of a USD 0.15 loss.
- Net loss was USD 82.11 million, compared with USD 3.73 million.
- Acquired in-process Research and Development was USD 79.91 million.
- The company completed its Cy Biopharma Acquisition on August 5, 2026.
Ensysce Biosciences (NASDAQ:ENSC) reported a third quarter 2026 loss per share of USD 4.52, against an estimate of a USD 0.15 loss and a USD 1.29 loss in the third quarter of 2025. The net loss was USD 82.11 million, compared with USD 3.73 million.
The company completed its previously announced acquisition of Cy Biopharma, Inc. on August 5, 2026, and the filing states that its lead development program is now CY200, a clinical-stage psilocybin-predominant botanical extract for the treatment of chronic pain conditions, including complex regional pain syndrome, which has received Orphan Drug Designation.
Operating Expenses
Research and development expenses were USD 3.2 million, compared with USD 3.0 million, an increase of USD 0.2 million. General and administrative expenses were USD 1.6 million, compared with USD 1.3 million, an increase of USD 0.3 million.
The quarter included acquired in-process research and development of USD 79.91 million, with none in the prior-year period. Total operating expenses were USD 84.68 million, compared with USD 4.23 million, and the loss from operations was USD 82.50 million, compared with USD 3.74 million.
Nine-Month Results
For the nine months ended September 30, 2026, the net loss was USD 88.24 million, compared with USD 7.41 million, and the loss per share was USD 6.95, compared with USD 3.42. Total operating expenses were USD 92.94 million, compared with USD 10.64 million, and the loss from operations was USD 88.63 million, compared with USD 7.46 million.
Research and development expenses for the nine months were USD 8.99 million, compared with USD 6.76 million, and general and administrative expenses were USD 4.04 million, compared with USD 3.88 million.
Cash Flow and Going Concern
Net cash used in Operating Activities for the nine months was USD 6.86 million, compared with USD 6.28 million. Net cash provided by investing activities was USD 11.39 million, compared with net cash used of USD 0.12 million, and the filing reports USD 11.44 million of cash from the acquisition of Assets from Cy Biopharma.
The filing states that other income and expense for the quarter consisted primarily of foreign exchange gains from the foreign subsidiaries acquired in the Cy acquisition. It also states that certain matters raise substantial doubt about the company's ability to continue as a going concern, and that its plans do not alleviate that substantial doubt for a period of 12 months following the date the financial statements were issued.
The filing notes that cumulative funding under an earlier grant of approximately USD 10.7 million was completed in December 2023, and describes proceeds from the issuance of Series C preferred stock in a private Placement among its financing activities.
Ensysce Biosciences Q3 2026 Earnings: Key Takeaways
Ensysce Biosciences reported a third quarter 2026 loss per share of USD 4.52 and a net loss of USD 82.11 million, which included USD 79.91 million of acquired in-process research and development. The filing includes a Going Concern disclosure.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...